Shares of ImmunoGen, Inc. (NASDAQ:IMGN) have been assigned a consensus recommendation of “Hold” from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.08.

Several brokerages have commented on IMGN. Canaccord Genuity reiterated a “buy” rating and set a $10.00 target price (up previously from $8.00) on shares of ImmunoGen in a research report on Wednesday, August 30th. BidaskClub upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Cantor Fitzgerald reiterated a “hold” rating on shares of ImmunoGen in a research report on Tuesday, August 29th. Jefferies Group LLC reiterated a “buy” rating and set a $9.00 target price on shares of ImmunoGen in a research report on Monday, August 7th. Finally, Cowen and Company reissued a “hold” rating on shares of ImmunoGen in a report on Tuesday, August 29th.

ImmunoGen (IMGN) traded down 5.36% during midday trading on Wednesday, hitting $7.24. The stock had a trading volume of 4,490,854 shares. ImmunoGen has a one year low of $1.51 and a one year high of $8.84. The company’s market cap is $648.68 million. The stock’s 50-day moving average is $6.36 and its 200-day moving average is $4.99.

ImmunoGen (NASDAQ:IMGN) last issued its earnings results on Friday, July 28th. The biotechnology company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.07. The business had revenue of $39.02 million for the quarter, compared to the consensus estimate of $30.59 million. The business’s revenue was up 426.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.53) EPS. Equities analysts predict that ImmunoGen will post ($0.74) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/09/06/immunogen-inc-imgn-receives-consensus-rating-of-hold-from-brokerages.html.

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in shares of ImmunoGen by 37,346.0% in the 1st quarter. JPMorgan Chase & Co. now owns 187,230 shares of the biotechnology company’s stock valued at $725,000 after buying an additional 186,730 shares during the period. Stifel Financial Corp grew its holdings in shares of ImmunoGen by 14.2% in the 1st quarter. Stifel Financial Corp now owns 103,815 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 12,907 shares during the period. Neuberger Berman Group LLC grew its holdings in shares of ImmunoGen by 8.2% in the 1st quarter. Neuberger Berman Group LLC now owns 47,943 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 3,616 shares during the period. Geode Capital Management LLC grew its holdings in shares of ImmunoGen by 3.5% in the 1st quarter. Geode Capital Management LLC now owns 678,343 shares of the biotechnology company’s stock valued at $2,625,000 after buying an additional 22,991 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of ImmunoGen by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,110,431 shares of the biotechnology company’s stock valued at $15,907,000 after buying an additional 27,141 shares during the period. 84.64% of the stock is owned by institutional investors.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.